Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 867Carcinoma, Non-Small-Cell Lung 637Prostatic Neoplasms 516Multiple Myeloma 441Neoplasms 425Leukemia, Myeloid, Acute 377Lymphoma 356Leukemia 335Melanoma 333Neoplasm Metastasis 321Lung Neoplasms 308Lymphoma, Non-Hodgkin 302Leukemia, Lymphocytic, Chronic, B-Cell 301Colorectal Neoplasms 281Ovarian Neoplasms 264Pancreatic Neoplasms 249Recurrence 240Precursor Cell Lymphoblastic Leukemia-Lymphoma 239Myelodysplastic Syndromes 233Glioblastoma 212Hodgkin Disease 201Lymphoma, Large B-Cell, Diffuse 197Lymphoma, Follicular 195Brain Neoplasms 194Carcinoma, Renal Cell 189Head and Neck Neoplasms 187Squamous Cell Carcinoma of Head and Neck 186Lymphoma, Mantle-Cell 171Sarcoma 158Fallopian Tube Neoplasms 139

Interventions

prednylidene 1deltacortene 1cabazitaxel 1XRP6258 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Has results × Hormone-Resistant Prostate Cancer × Clear all
NCT02844582 2021-01-25

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of California, Davis

Phase 2 Terminated
2 enrolled 5 charts
Genitourinary

Hormone-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡